Promise and Implementation of Proteomic Prostate Cancer Biomarkers

Prostate cancer is one of the most commonly diagnosed malignancy and the fifth leading cause of cancer mortality in men. Despite the broad use of prostate-specific antigen test that resulted in an increase in number of diagnosed cases, disease management needs to be improved. Proteomic biomarkers alone and or in combination with clinical and pathological risk calculators are expected to improve on decreasing the unnecessary biopsies, stratify low risk patients, and predict response to treatment. To this end, significant efforts have been undertaken to identify novel biomarkers that can accurately discriminate between indolent and aggressive cancer forms and indicate those men at high risk for developing prostate cancer that require immediate treatment. In the era of "big data" and "personalized medicine" proteomics-based biomarkers hold great promise to provide clinically applicable tools, as proteins regulate all biological functions, and integrate genomic information with the environmental impact. In this review article, we aim to provide a critical assessment of the current proteomics-based biomarkers for prostate cancer and their actual clinical applicability. For that purpose, a systematic review of the literature published within the last 10 years was performed using the Web of Science Database. We specifically discuss the potential and prospects of use for diagnostic, prognostic and predictive proteomics-based biomarkers, including both body fluid- and tissue-based markers.

Diagnostics (Basel, Switzerland). 2018 Aug 29*** epublish ***

Agnieszka Latosinska, Maria Frantzi, Axel S Merseburger, Harald Mischak

Mosaiques Diagnostics GmbH, 30659 Hannover, Germany. ., Mosaiques Diagnostics GmbH, 30659 Hannover, Germany. ., Department of Urology, University Clinic of Schleswig-Holstein, Campus Lübeck, 23562 Lübeck, Germany. ., Mosaiques Diagnostics GmbH, 30659 Hannover, Germany. .